Equities analysts expect that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will post sales of $3.60 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $3.50 million and the highest is $3.70 million. Pieris Pharmaceuticals reported sales of $1.34 million in the same quarter last year, which indicates a positive year-over-year growth rate of 168.7%. The business is scheduled to issue its next earnings results on Thursday, March 8th.
According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year sales of $3.60 million for the current financial year, with estimates ranging from $10.50 million to $15.80 million. For the next financial year, analysts anticipate that the business will post sales of $12.17 million per share, with estimates ranging from $10.00 million to $15.20 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Pieris Pharmaceuticals.
A number of analysts have commented on the company. BidaskClub downgraded Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 17th. HC Wainwright set a $12.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, February 9th. ValuEngine raised Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, William Blair started coverage on Pieris Pharmaceuticals in a report on Wednesday, January 17th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $10.00.
In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 1,709,620 shares of the stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $7.35, for a total value of $12,565,707.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,865,152 shares of company stock worth $13,478,142 over the last quarter. Corporate insiders own 4.05% of the company’s stock.
Several large investors have recently bought and sold shares of the company. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Pieris Pharmaceuticals in the 4th quarter valued at about $3,370,000. Teachers Advisors LLC bought a new stake in shares of Pieris Pharmaceuticals during the second quarter worth approximately $308,000. JPMorgan Chase & Co. bought a new stake in shares of Pieris Pharmaceuticals during the third quarter worth approximately $600,000. Creative Planning boosted its holdings in shares of Pieris Pharmaceuticals by 18.2% during the fourth quarter. Creative Planning now owns 78,025 shares of the biotechnology company’s stock worth $589,000 after acquiring an additional 12,000 shares during the period. Finally, Strs Ohio boosted its holdings in shares of Pieris Pharmaceuticals by 1,028.0% during the fourth quarter. Strs Ohio now owns 112,800 shares of the biotechnology company’s stock worth $851,000 after acquiring an additional 102,800 shares during the period. Institutional investors and hedge funds own 47.19% of the company’s stock.
Pieris Pharmaceuticals (PIRS) traded down $0.13 during trading on Thursday, reaching $7.27. The company had a trading volume of 2,180,000 shares, compared to its average volume of 1,150,437. The firm has a market cap of $364.99, a price-to-earnings ratio of -17.73 and a beta of 1.50. Pieris Pharmaceuticals has a 12-month low of $2.26 and a 12-month high of $9.75.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/11/3-60-million-in-sales-expected-for-pieris-pharmaceuticals-inc-pirs-this-quarter.html.
Pieris Pharmaceuticals Company Profile
Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.
Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.